Sees FY26 gross margin 77%-79%. “Our performance continues to be led by EXPAREL, which is benefitting from expanding reimbursement, growing commercial adoption, and strengthened intellectual property providing protection into the 2040s. We further extended our commercial reach through strategic collaborations, while advancing clinical programs positioned to deliver a data-rich year. Pacira (PCRX) enters 2026 stronger than ever as we continue to redefine what is possible in innovative non-opioid pain management,” continued Lee.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX:
- PCRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Pacira Biosciences (PCRX) Securities Lawsuit Dismissed by New Jersey Federal Court
- Pacira highlights new NOPAIN act survey data conducted by Voices
- Pacira reports inducement grants under Nasdaq listing rule
- Pacira BioSciences adds seasoned leader to board